03 September 2010
Keywords: Multiple Sclerosis, MS, Novartis, Extavia
Article | 17 August 2009
The US Food and Drug Administration (FDA) has approved Extavia (interferon beta-1b), the first in a new planned portfolio of multiple sclerosis (MS) medicines from Novartis to help patients manage this devastating disease.
Extavia, acquired by the Swiss firm as part of its purchase of Chiron in 2005, is approved by the FDA for the treatment of relapsing forms of MS to reduce the frequency of clinical exacerbations. Enjoying this article? To continue reading you need to login, take a FREE trial or subscribe.
FREE unlimited, no obligation access to The Pharma Letter website for 30 days, normally worth £60!
Sign up in less than 60 seconds...no payment needed
Take a no obligations 30 day trial.
Only one trial per user. Find out more details
Subscriptions are £60 per month, pay as you go.
Find out more details.